PMID- 16639341
OWN - NLM
STAT- MEDLINE
DCOM- 20060629
LR  - 20201209
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 42
IP  - 1
DP  - 2006 May
TI  - Coadministration of esomeprazole with fosamprenavir has no impact on steady-state 
      plasma amprenavir pharmacokinetics.
PG  - 61-7
AB  - OBJECTIVES: To evaluate the drug interaction between fosamprenavir (FPV) and 
      esomeprazole (ESO) after repeated doses in healthy adults. METHODS: Subjects 
      received ESO 20 mg once daily (qd) for 7 days followed by either ESO 20 mg qd + 
      FPV 1400 mg twice daily (bid) or ESO 20 mg qd + FPV 700 mg bid + ritonavir (RTV) 
      100 mg bid for 14 days in arms 1 and 2, respectively. After a 21- to 28-day 
      washout, subjects received either FPV 1400 mg bid for 14 days (arm 1) or FPV 700 
      mg bid + RTV 100 mg bid for 14 days (arm 2). Pharmacokinetic sampling was 
      conducted on the last day of each treatment. RESULTS: Simultaneous 
      coadministration of ESO 20 mg qd with either FPV 1400 mg bid or FPV 700 mg bid + 
      RTV 100 mg bid had no effect on steady-state amprenavir pharmacokinetics. The 
      only effect on plasma ESO exposure was a 55% increase in area under the plasma 
      concentration-time curve during a dosing interval, tau[AUC0-tau], after 
      coadministration of ESO 20 mg qd with FPV 1400 mg bid. CONCLUSIONS: FPV 1400 mg 
      bid or FPV 700 mg bid + RTV 100 mg bid may be coadministered simultaneously with 
      ESO without dose adjustment. However, the impact of staggered administration of 
      proton pump inhibitors (PPI) on plasma amprenavir exposure is unknown at present.
FAU - Shelton, Mark J
AU  - Shelton MJ
AD  - Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle 
      Park, NC 27709, USA. Mark.J.Shelton@GSK.com
FAU - Ford, Susan L
AU  - Ford SL
FAU - Borland, Julie
AU  - Borland J
FAU - Lou, Yu
AU  - Lou Y
FAU - Wire, Mary B
AU  - Wire MB
FAU - Min, Sherene S
AU  - Min SS
FAU - Xue, Zhengyu G
AU  - Xue ZG
FAU - Yuen, Geoffrey
AU  - Yuen G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Carbamates)
RN  - 0 (Drug Combinations)
RN  - 0 (Furans)
RN  - 0 (Organophosphates)
RN  - 0 (Sulfonamides)
RN  - 5S0W860XNR (amprenavir)
RN  - N3PA6559FT (Esomeprazole)
RN  - O3J8G9O825 (Ritonavir)
RN  - WOU1621EEG (fosamprenavir)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Carbamates/*administration & dosage/adverse effects/blood/*pharmacokinetics
MH  - Diarrhea/chemically induced
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Esomeprazole/*administration & dosage/adverse effects
MH  - Female
MH  - Furans
MH  - Headache/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Organophosphates/*administration & dosage/adverse effects
MH  - Ritonavir/administration & dosage/adverse effects
MH  - Sulfonamides/*administration & dosage/adverse effects/blood/*pharmacokinetics
EDAT- 2006/04/28 09:00
MHDA- 2006/06/30 09:00
CRDT- 2006/04/28 09:00
PHST- 2006/04/28 09:00 [pubmed]
PHST- 2006/06/30 09:00 [medline]
PHST- 2006/04/28 09:00 [entrez]
AID - 10.1097/01.qai.0000219770.97303.43 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2006 May;42(1):61-7. doi: 
      10.1097/01.qai.0000219770.97303.43.